These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 17606880)

  • 1. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy.
    Niermeijer JM; Eurelings M; van der Linden MW; Lokhorst HM; Franssen H; Fischer K; Teunissen LL; van den Berg LH; Schobben F; Wokke JH; Notermans NC
    Neurology; 2007 Jul; 69(1):50-9. PubMed ID: 17606880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study.
    Niermeijer JM; Fischer K; Eurelings M; Franssen H; Wokke JH; Notermans NC
    Neurology; 2010 Feb; 74(5):406-12. PubMed ID: 20124206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy.
    Niermeijer JM; Eurelings M; Lokhorst H; Franssen H; Fijnheer R; Wokke JH; Notermans NC
    Neurology; 2006 Dec; 67(11):2076-9. PubMed ID: 17159126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies.
    van Everdingen AA; Siewertsz van Reesema DR; Jacobs JW; Bijlsma JW
    Arthritis Rheum; 2004 Apr; 51(2):233-8. PubMed ID: 15077265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance.
    Notermans NC; Lokhorst HM; Franssen H; Van der Graaf Y; Teunissen LL; Jennekens FG; Van den Berg LH; Wokke JH
    Neurology; 1996 Nov; 47(5):1227-33. PubMed ID: 8909434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous cyclophosphamide in refractory polyneuropathy associated with IgM monoclonal gammopathy: an uncontrolled open trial.
    Hamidou MA; Belizna C; Wiertlewsky S; Audrain M; Biron C; Grolleau JY; Mussini JM
    Am J Med; 2005 Apr; 118(4):426-30. PubMed ID: 15808143
    [No Abstract]   [Full Text] [Related]  

  • 8. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
    Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
    Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
    Khanna D; Yan X; Tashkin DP; Furst DE; Elashoff R; Roth MD; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M; Clements PJ;
    Arthritis Rheum; 2007 May; 56(5):1676-84. PubMed ID: 17469162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for polyneuropathy with IgM monoclonal gammopathy.
    Niermeijer JM; Eurelings M; Lokhorst HL; van der Pol WL; Franssen H; Wokke JH; Notermans NC
    J Neurol Neurosurg Psychiatry; 2009 Sep; 80(9):1036-9. PubMed ID: 19684235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance.
    Dyck PJ; Low PA; Windebank AJ; Jaradeh SS; Gosselin S; Bourque P; Smith BE; Kratz KM; Karnes JL; Evans BA
    N Engl J Med; 1991 Nov; 325(21):1482-6. PubMed ID: 1658648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial.
    Lizogub VG; Riley DS; Heger M
    Explore (NY); 2007; 3(6):573-84. PubMed ID: 18005909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized placebo-controlled double-blind study of levamisole in the treatment of limited and slowly spreading vitiligo.
    Agarwal S; Ramam M; Sharma VK; Khandpur S; Pal H; Pandey RM
    Br J Dermatol; 2005 Jul; 153(1):163-6. PubMed ID: 16029343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy.
    Dalakas MC; Quarles RH; Farrer RG; Dambrosia J; Soueidan S; Stein DP; Cupler E; Sekul EA; Otero C
    Ann Neurol; 1996 Nov; 40(5):792-5. PubMed ID: 8957021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial.
    Beenakker EA; Fock JM; Van Tol MJ; Maurits NM; Koopman HM; Brouwer OF; Van der Hoeven JH
    Arch Neurol; 2005 Jan; 62(1):128-32. PubMed ID: 15642859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of idiopathic sudden sensorineural hearing loss using pulse therapy: a prospective, randomized, double-blind clinical trial.
    Westerlaken BO; de Kleine E; van der Laan B; Albers F
    Laryngoscope; 2007 Apr; 117(4):684-90. PubMed ID: 17415139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.
    Benedetti L; Briani C; Grandis M; Vigo T; Gobbi M; Ghiglione E; Carpo M; Cocito D; Caporale CM; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
    J Peripher Nerv Syst; 2007 Jun; 12(2):102-7. PubMed ID: 17565535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.